Neurofibromatosis type 1 system-based manifestations and treatments: a review-Reference-Cited by-同舟云学术

Neurofibromatosis type 1 system-based manifestations and treatments: a review

Published:2023-02-24 Issue:6 Volume:44 Page:1931-1947
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Saleh Mustafa^ORCID,Dib AlFadel^ORCID,Beaini Sarah^ORCID,Saad Charbel^ORCID,Faraj Sary^ORCID,El Joueid Youssef^ORCID,Kotob Yasmine,Saoudi Lara,Emmanuel Nancy^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-023-06680-5.pdf

Reference50 articles.

1. Uusitalo E, Leppävirta J, Koffert A et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135(3):904–906. https://doi.org/10.1038/jid.2014.465

2. Gross AM, Dombi E, Widemann BC (2020) Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Child Nervous Syst 36(10):2443–2452. https://doi.org/10.1007/s00381-020-04731-2 (https://www.ncbi.nlm.nih.gov/pubmed/32607696)

3. Foiadelli T, Naso M, Licari A et al (2020) Advanced pharmacological therapies for neurofibromatosis type 1-related tumors. Acta Bio-Medica Atenei Parmensis 91(7-S):101–114. https://doi.org/10.23750/abm.v91i7-S.9961 (https://www.ncbi.nlm.nih.gov/pubmed/32608378)

4. Rabab’h Omar, Gharaibeh Abeer, Al-Ramadan Ali, Ismail Manar, Shah Jawad (2021) Pharmacological approaches in neurofibromatosis type 1-associated nervous system tumors. Cancers 13(15):3880. https://doi.org/10.3390/cancers13153880 (https://search.proquest.com/docview/2558730913)

5. Walker JA, Upadhyaya M (2018) Emerging therapeutic targets for neurofibromatosis type 1. Expert Opin Ther Targets 22(5):419–437. https://doi.org/10.1080/14728222.2018.1465931 (https://pubmed.ncbi.nlm.nih.gov/29667529)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example;Frontiers in Pharmacology;2024-08-13

2. Multiparametric whole-body MRI of patients with neurofibromatosis type I: spectrum of imaging findings;Skeletal Radiology;2024-08-06

3. Clinicopathologic characteristics of de novo NF1 -mutated acute myeloid leukemia;Leukemia & Lymphoma;2024-07-27

4. Hallux Flexion Deformity Secondary to Fibula Harvesting in a 10-Year-Old Patient With Neurofibromatosis;Cureus;2024-06-06

5. Volumetric measurement techniques for assessment of cutaneous neurofibromas: A review;Chinese Journal of Plastic and Reconstructive Surgery;2024-06